Table 2 Clinical effects of monotherapeutic PD-1 signal inhibitors on several types of malignancies

melanoma

pembrolizumab

2

6MOS 34% (2 mg/kg) vs. 38% (10 mg/kg), vs 16% :docetaxel (n = 540)

[88]

3

1 year-OS 74% (2wks) vs. 38% (3wks), vs 11% :docetaxel (n = 834)

[89]

nivolumab

3

1 year-OS 73% vs 42% (dacarbazine) (n = 418)

[89]

3

ORR 32% vs. 11% (dacarbazine) (n = 405)

[90]

non-small cell lung cancer

pembrolizumab

1

ORR 19.4%, mOS12.5 M (total), ORR 45.2% (n = 72, PD-L1+) (n = 495)

[91]

nivolumab

3

mOS 9.2 M (vs 6.0 M:docetaxel) (n = 272)

[57]

3

mOS12.2 M (vs 9.7 M:docetaxel (n = 582)

[92]

durvalumab

1/2

ORR 14% (n = 149, total), 23% (PD-L1+)

[72]

atezolizumab

2

ORR 15% (n = 144, total), 38% (n = 24, PD-L1+)

[93]

small cell lung cancer

nivolumab

1/2

ORR 18% (n = 40, nivo), 17% (n = 46, combined with chemotherapy)

[94]

pembrolizumab

1

ORR 25% (n = 16)

[95]

head and neck cancer

durvalumab

1/2

ORR 12% (n = 62)

[96]

pembrolizumab

1

ORR 24.8% (n = 117)

[97]

renal cell cancer

nivolumab

3

ORR 25%, mOS 25.0 M, (vs. ORR 5%, mOS 19Ms in everolimus) (n = 821)

[98]

bladder cancer

atezolizumab

1

ORR 26% (n = 310, total), 43% (PD-L1+)

[99]

pembrolizumab

1

ORR 25% (n = 33, total), 38% (PD-L1+)

[100]

ovarian cancer

nivolumab

2

ORR 15% (n = 20, total), mOS 20.0 M ORR 20% (n = 10, 3 mg/kg)

[60]

avelumab

1

ORR 10% (n = 124)

[101]

pembrolizumab

1

ORR 11.5% (PD-L1+) (n = 49)

[63]

uterine endometrial cancer

pembrolizumab

1

ORR 12.5% (PD-L1+) (n = 24)

[102]

uterine cervical cancer

pembrolizumab

1

ORR 12.5% (PD-L1+) (n = 24)

[103]

uterine sarcoma

nivolumab

1

ORR 0% (n = 12)

[104]

gastric cancer

pembrolizumab

1

ORR 31% (n = 39)

[79]

esophageal cancer

pembrolizumab

1

ORR 30% (PD-L1+) (n = 23)

[105]

DNA mismatch repair deficient colon

pembrolizumab

2

ORR 40% (n = 10, MMRd colon), vs 0% (n = 18) in MMRw, vs71% (n = 7), MMR-non-colon [cholangiocarcinoma, endometrial cancer and pancreatic cancer].)

[73].

DNA mismatch repair deficient endometrial cancer

pembrolizumab

2

ir-ORR 67% (n = 9)

[106]

hepatocellular carcinoma

nivolumab

1/2

ORR 9% (n = 91), 6 month-OS 69%.

[107]

breast cancer

atezolizumab

1

ORR 12% (n = 27)

[108]

pembrolizumab

1

ORR 19% (n = 25) (PD-L1+)

[109]

Merkel cell carcinoma

pembrolizumab

2

ORR 56% (n = 25), 6 M-PFS 67%

[110]

thyroid cancer

pembrolizumab

1

ORR 9.1% (n = 22), mOS not reached, 1 year-OS 89.9%.

[111]

Hodgikin lymphoma

nivolumab

1

ORR 87%, 24wks-PFS 86%(n = 23)

[112]

pembrolizumab

1

ORR 64% (n = 31), 52wks-PFS 46%.

[113]

follicular lymphoma

nivolumab

1

ORR 40% (n = 10)

[114]

diffuse large B-cell lymphoma

nivolumab

1

ORR 36% (n = 11)

[114]

mycosisfungoides

nivolumab

1

ORR 15% (n = 13)

[114]

peripheral T-cell lymphoma

nivolumab

1

ORR 40% (n = 5)

[114]